| Angioedemas, Hereditary
Orladeyo vs Kalbitor
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Orladeyo vs Kalbitor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKalbitor has a higher rate of injection site reactions vs Orladeyo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kalbitor but not Orladeyo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Orladeyo
Kalbitor
At A Glance
Oral
Once daily
Plasma kallikrein inhibitor
SC injection
As needed
Plasma kallikrein inhibitor
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary (adults and pediatric patients >=12 years) 150 mg capsule orally once daily with food; reduce to 110 mg once daily with food for moderate or severe hepatic impairment (Child-Pugh Class B or C).
Angioedemas, Hereditary (pediatric patients 2 to <12 years) Weight-based oral pellets once daily with food: 72 mg (12 to <24 kg), 96 mg (24 to <32 kg), 108 mg (32 to <40 kg), or 132 mg (>=40 kg); avoid use in moderate or severe hepatic impairment.
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Contraindications
—
- Known clinical hypersensitivity to KALBITOR
Adverse Reactions
Most common (>=10%) Abdominal pain, vomiting, diarrhea, back pain, gastroesophageal reflux disease
Serious QTc interval prolongation (at supratherapeutic doses), transaminase elevations
Postmarketing Nausea
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Pharmacology
Plasma kallikrein inhibitor; berotralstat binds to and inhibits plasma kallikrein's proteolytic activity, thereby reducing bradykinin generation and preventing angioedema attacks in patients with HAE due to C1-inhibitor deficiency or dysfunction.
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Orladeyo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Orladeyo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Orladeyo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OrladeyoView full Orladeyo profile
KalbitorView full Kalbitor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.